These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 6334579)
1. Inhibition of interleukin-2 production by adherent cell factors from lepromatous leprosy patients. Nath I; Jayaraman J; Sathish M; Bhutani LK; Sharma AK Clin Exp Immunol; 1984 Dec; 58(3):531-8. PubMed ID: 6334579 [TBL] [Abstract][Full Text] [Related]
2. Evidence for the presence of M. leprae reactive T lymphocytes in patients with lepromatous leprosy. Nath I; Sathish M; Jayaraman T; Bhutani LK; Sharma AK Clin Exp Immunol; 1984 Dec; 58(3):522-30. PubMed ID: 6391762 [TBL] [Abstract][Full Text] [Related]
3. Analysis of cytokine production by Mycobacterium-reactive T cells. Failure to explain Mycobacterium leprae-specific nonresponsiveness of peripheral blood T cells from lepromatous leprosy patients. Mutis T; Kraakman EM; Cornelisse YE; Haanen JB; Spits H; De Vries RR; Ottenhoff TH J Immunol; 1993 May; 150(10):4641-51. PubMed ID: 8482851 [TBL] [Abstract][Full Text] [Related]
4. Defective cell-mediated immunity in leprosy: failure of T cells from lepromatous leprosy patients to respond to Mycobacterium leprae is associated with defective expression of interleukin 2 receptors and is not reconstituted by interleukin 2. Mohagheghpour N; Gelber RH; Larrick JW; Sasaki DT; Brennan PJ; Engleman EG J Immunol; 1985 Aug; 135(2):1443-9. PubMed ID: 2989366 [TBL] [Abstract][Full Text] [Related]
5. In vivo responses to Mycobacterium leprae: antigen presentation, interleukin-2 production, and immune cell phenotypes in naturally occurring leprosy lesions. Longley J; Haregewoin A; Yemaneberhan T; Warndorff van Diepen T; Nsibami J; Knowles D; Smith KA; Godal T Int J Lepr Other Mycobact Dis; 1985 Sep; 53(3):385-94. PubMed ID: 3900245 [TBL] [Abstract][Full Text] [Related]
6. Spontaneous production of a suppressor factor by a human macrophage-like cell line U937. II. Suppression of antigen- and mitogen-induced blastogenesis, IL 2 production and IL 2 receptor expression in T lymphocytes. Fujiwara H; Toossi Z; Ohnishi K; Edmonds K; Ellner JJ J Immunol; 1987 Jan; 138(1):197-203. PubMed ID: 3097146 [TBL] [Abstract][Full Text] [Related]
7. Reversal of T cell anergy in leprosy patients: in vitro presentation with Mycobacterium leprae antigens using murabutide and Trat peptide in liposomal delivery. Sridevi K; Khanna N; Chattree V; Pal PC; Haq W; Rao DN Int Immunopharmacol; 2003 Nov; 3(12):1589-600. PubMed ID: 14555284 [TBL] [Abstract][Full Text] [Related]
8. Evidence of cell-mediated immune contrasuppression in lepromatous leprosy: modulation of a putative T contrasuppressor cell-subset. González-Amaro R; Salazar-González JF; Baranda L; Abud-Mendoza C; Moncada B; García R; Alcocer-Varela J Clin Exp Immunol; 1988 Mar; 71(3):399-404. PubMed ID: 3133142 [TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive roles for IL-10 and IL-4 in human infection. In vitro modulation of T cell responses in leprosy. Sieling PA; Abrams JS; Yamamura M; Salgame P; Bloom BR; Rea TH; Modlin RL J Immunol; 1993 Jun; 150(12):5501-10. PubMed ID: 8515073 [TBL] [Abstract][Full Text] [Related]
10. Effect of phorbol myristate acetate (PMA) and ionophore A23187 on interleukin-2 levels and proliferation of activated T lymphocytes from patients with lepromatous leprosy. Alfaro-Bustamante F; Ramirez-Flores G; Gonzalez-Mendoza A; Islas-Rodriguez A; Fafutis-Morris M Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):73-9. PubMed ID: 9207756 [TBL] [Abstract][Full Text] [Related]
11. The suppressive effect of M. leprae on the in vitro proliferative responses of lymphocytes from patients with leprosy. Nath I; Singh R Clin Exp Immunol; 1980 Sep; 41(3):406-14. PubMed ID: 7002396 [TBL] [Abstract][Full Text] [Related]
12. In situ identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin 2 and its receptor. Modlin RL; Hofman FM; Horwitz DA; Husmann LA; Gillis S; Taylor CR; Rea TH J Immunol; 1984 Jun; 132(6):3085-90. PubMed ID: 6327818 [TBL] [Abstract][Full Text] [Related]
14. Immunologic defects in leprosy patients. II. Interleukin 1, interleukin 2, and interferon production in leprosy patients. Makonkawkeyoon S; Kasinrerk W; Supajatura V; Hirunpetcharat C; Vithayasai V Int J Lepr Other Mycobact Dis; 1990 Jun; 58(2):311-8. PubMed ID: 1695911 [TBL] [Abstract][Full Text] [Related]
15. Radiolabelled M. leprae resident in human macrophage cultures as an in vitro indicator of effective immunity in human leprosy. Prasad HK; Singh R; Nath I Clin Exp Immunol; 1982 Sep; 49(3):517-22. PubMed ID: 6756718 [TBL] [Abstract][Full Text] [Related]
16. Monocyte-derived soluble suppressor factor(s) in patients with lepromatous leprosy. Sathish M; Bhutani LK; Sharma AK; Nath I Infect Immun; 1983 Dec; 42(3):890-9. PubMed ID: 6605932 [TBL] [Abstract][Full Text] [Related]
17. Concanavalin A-induced human lymphocyte mitogenic factor: activity distinct from interleukin 1 and 2. Duncan MR; George FW; Hadden JW J Immunol; 1982 Jul; 129(1):56-62. PubMed ID: 6806367 [TBL] [Abstract][Full Text] [Related]